Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Anthem

Bristol-Myers

Cigna

As Mr. Valuation, I find myself constantly reminding investors that value investing requires patience. However, value investing also requires the willingness to get your money in front of attractive valuation when it is discovered. Trying to time your purchases perfectly can just as easily cause you to miss out on significant gains as it is to participate in them. More directly stated, significant undervaluation can stimulate strong pent-up demand causing stock prices to rise rapidly. Therefore, if you are not already in front of those advances, you can miss out on a lot of profit and opportunity.

5 Leading Healthcare Stocks Surging On Pent-Up Demand

GlaxoSmithKline

GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in the long term, but would opt for GSK due to its lesser focus on oncology, a market that is becoming more and more crowded.

GlaxoSmithKline Or AbbVie: Choices In High-Yield Pharma

AbbVie delivered yet another robust dividend increase, building on its dividend increase streak since it was spun off from Abbott Laboratories in 2013. AbbVie's operating fundamentals have remained strong despite COVID-19, with the company posting 13.2% YTD YoY adjusted diluted EPS growth.

AbbVie: Delivering Yet Another Double-Digit Dividend Increase

Apple

Alibaba

Home Depot

McDonald's

Shopify

Blue-chip stocks can generate large returns over time, making for great investments in a turbulent economy. Here are my top 7 picks.

7 Stable Blue-Chip Stocks for Today's Volatile Economy

National Retail Properties

28 dividend payments brought income up delightfully by 10.2% from 2019 and up 11.7% from July 2020. Scary is the total portfolio value is down year to date by 10.2% including dividends and option cash with 2.4% of it just from October.

The 92 Stock Rose Portfolio October Update And Quality Evaluation Buy List

AbbVie stock slipped when a House committee looking at drug prices said it would issue a subpoena, but the Allergan owner is working on coronavirus treatments. Is AbbVie stock a buy now?

AbbVie Joins The Coronavirus Drug Hunt — Is AbbVie Stock A Buy?

NORTH CHICAGO, Ill., Nov. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it will present blood cancer data from nearly 40 abstracts, including 10 oral presentations, across 11 cancer types during the upcoming virtual American Society of Hematology (ASH) Annual Meeting and...

AbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting

AbbVie (ABBV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

AbbVie (ABBV) in Focus: Stock Moves 7.4% Higher

Aflac

Amcor Plc

Franklin Resources

Cardinal Health

Chevron

Federal Realty Investment Trust

Johnson & Johnson

Realty Income Corp

People's United Financial

Raytheon Technologies

AT&T

Walgreens

Exxon Mobil

"S&P 500® Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years."---us.spindices.com. The 65 Aristocrats of November 2020 represent ten of eleven Morningstar Sectors (no Technology). Broker targeted-top-ten net-gainers ranged 19.36%-45.91% topped by XOM & CVX 11/3/20.

65 November Dividend Aristocrats

Shares of AbbVie Inc.(NYSE:ABBV) have soared nearly 18% less than a week after the company reported outstanding results for the third quarter and upped its guidance for the full year.

AbbVie Shares Soar on 3rd-Quarter Results, Bright Outlook

Global X China Biotech Innovation ETF

Royalty Pharma

Investing in biotech stocks may feel daunting to many investors, but these three stocks deserve to be on your watchlist. The post 3 Biotech Stocks With Eye-Catching Pipelines appeared first on InvestorPlace.

3 Biotech Stocks With Eye-Catching Pipelines

AbbVie Inc. (NYSE:ABBV), a name I have felt is undervalued for some time, reported third-quarter earnings results Friday morning that easily topped Wall Street's estimates. The company also gave yet another double-digit dividend increase.

Pounding the Table for AbbVie

AbbVie Inc.'s (ABBV) CEO Rick Gonzalez on Q3 2020 Results - Earnings Call Transcript

A strong performance from Humira was a big factor in the pharmaceutical company's success.

How AbbVie Beat Expectations in Q3

AbbVie (ABBV) news for Friday includes results from the biopharmaceutical company's earnings report for the third quarter of 2020. The post AbbVie News: 5 Things for ABBV Investors to Know About Q3 appeared first on InvestorPlace.

AbbVie News: 5 Things for ABBV Investors to Know About Q3

AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.

AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance

Yamana Gold

Capital One

McKesson

International sales accounted for 59 percenDaily Dividend Report: Apple, Capital One Financial, Yamana Gold, AbbVie, Walgreens Boots Alliance, McKessont of the quarter's revenue.

Daily Dividend Report: Apple, Capital One Financial, Yamana Gold, AbbVie, Walgreens Boots Alliance, McKesson

AbbVie (ABBV) delivered earnings and revenue surprises of 2.91% and 1.83%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q3 Earnings and Revenues Top Estimates

Shares of AbbVie Inc. gained 0.2% in premarket trading Friday, after the biopharmaceutical and health care company reported third-quarter earnings that beat expectations, raised its full-year outlook and boosted its dividend by 10%. Net income rose to $2.31 billion, or $1.29 a share, from $1.88 billion, or $1.26 a share, in the year-ago period.

AbbVie beats earnings expectations, raises its outlook and boosts dividend

AbbVie earnings topped third-quarter views, helped by rising Humira sales. ABBV stock rose modestly before Friday's market open.

AbbVie Earnings Top Views On Rising Humira Sales

Drugmaker AbbVie Inc posted better-than-expected quarterly sales and raised its full-year adjusted profit forecast on Friday, as demand for its Botox and other treatments showed signs of recovery from the COVID-19 pandemic hit.

AbbVie raises 2020 profit forecast as COVID-19 hit eases

Gilead Sciences

These two drugmakers are unlikely to slash or suspend their dividend payments -- even in the midst of a recession.

2 No-Brainer Dividend Stocks Yielding More Than 4%

NORTH CHICAGO, Ill., Oct. 29, 2020 /PRNewswire/ -- Late-breaking data analyses to be presented by AbbVie (NYSE: ABBV) at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15...

AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis

AbbVie's (ABBV) Q3 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.

Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q3 Earnings?

bluebird bio

Mustang Bio

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

News for AbbVie Stock (ABBV)